Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | Director | May 19, 2023 | May 23, 2023 |
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | Director | February 01, 2013 | February 05, 2013 |
| LABCORP HOLDINGS INC.LH · Entity 1277 | Director | February 06, 2024 | February 08, 2024 |
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | Director | May 28, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date May 19, 2023 · Filed May 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,240 |
Reported balance
After 2023-05-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-05-19 · Grant · Acquired 939 · Balance 6,240 F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.
BRISTOL MYERS SQUIBB CO
Report date February 01, 2013 · Filed February 05, 2013
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 48,335.71 |
Reported balance
After 2013-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2013-02-01 · Grant · Acquired 4,364 · Balance 48,335.71 F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
LABCORP HOLDINGS INC.
Report date February 06, 2024 · Filed February 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,120 |
Reported balance
After 2024-02-07 transaction · row 1
1 source rowRow 1 · 2024-02-07 · Exercise / conversion · Acquired 947 · Balance 8,120 F1: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 1,183 |
Reported balance
After 2024-02-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-06 · Grant · Acquired 236 · Balance 1,183 F1: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2: The Restricted Stock Units vest fully on February 6, 2025. F3: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 98 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 236 |
Reported balance
After 2024-02-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-07 · Exercise / conversion · Disposed 947 · Balance 236 F1: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4: The Restricted Stock Units vested fully on February 7, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
F2: The Restricted Stock Units vest fully on February 6, 2025.
F3: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 98 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.
F4: The Restricted Stock Units vested fully on February 7, 2024.
Tenaya Therapeutics, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2036-05-27 | Direct | 120,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 120,000 · Balance 120,000 F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2026 Filed May 29, 2026 23:30 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 120,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001193125-26-249135 · ownership.xml · derivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2036-05-27 F1 · derivative.exercise_date: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| May 29, 2025 Filed May 30, 2025 22:51 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 107,400 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0000950170-25-079946 · ownership.xml · derivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,400 Underlying: Common Stock · 107,400 shares Expires 2035-05-28 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 00:42 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 34,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0000950170-24-116064 · ownership.xml · derivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2034-10-17 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 31, 2025, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:52 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003895 · form4.xml · derivative · entry 3 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236 Underlying: Common Stock · 947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vested fully on February 7, 2024. F4 · derivative.expiration_date: The Restricted Stock Units vested fully on February 7, 2024. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:52 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003895 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 17:52 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 236 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003895 · form4.xml · derivative · entry 2 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,183 Underlying: Common Stock · 236 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 6, 2025. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 6, 2025. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 98 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 00:38 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 29,532 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001209191-23-036523 · doc4.xml · derivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,532 Underlying: Common Stock · 29,532 shares Expires 2033-06-08 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| May 19, 2023 Filed May 23, 2023 23:29 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 939 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016642 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,240 F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:07 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005106 · form4.xml · derivative · entry 2 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849 Underlying: Common Stock · 742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 11, 2023. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:07 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 742 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005106 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 17:20 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 849 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004125 · form4.xml · derivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,591 Underlying: Common Stock · 849 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 7, 2024. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 7, 2024. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 01:03 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 200 | $249.96 | $49,992.00 |
DisclosureSEC source: 0001127602-22-021453 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,301 F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:41 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 39,727 | $0.00 Strike: $5.26 | $0.00 |
DisclosureSEC source: 0001209191-22-036519 · doc4.xml · derivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,727 Underlying: Common Stock · 39,727 shares Expires 2032-06-09 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| May 23, 2022 Filed May 24, 2022 01:19 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 600 | $250.00 | $150,000.00 |
DisclosureSEC source: 0001127602-22-015409 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,501 F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. Read SEC document |
| May 17, 2022 Filed May 20, 2022 01:58 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 855 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-015182 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,101 F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 13:46 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 572 | $272.98 | $156,144.56 |
DisclosureSEC source: 0001127602-22-010475 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,431 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 01:29 UTC Amendment | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005193 · form4a.xml · derivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742 Underlying: Common Stock · 742 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2023. F3 · derivative.exercise_date: This form is being amended solely to correct the vesting schedule, which was previously reported incorrectly due to an administrative error. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2023. F3 · derivative.expiration_date: This form is being amended solely to correct the vesting schedule, which was previously reported incorrectly due to an administrative error. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 17:37 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004962 · form4.xml · derivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742 Underlying: Common Stock · 742 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 9, 2017. F3 · derivative.expiration_date: The Restricted Stock Units vest fully on February 12, 2019. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 14:11 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 771 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003272 · form4.xml · derivative · entry 2 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 771 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 2, 2022. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 14:11 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 771 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003272 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| May 18, 2021 Filed May 20, 2021 01:24 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 837 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-017471 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,246 F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. Read SEC document |
| May 07, 2021 Filed May 10, 2021 22:38 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 250 | $251.78 | $62,945.00 |
DisclosureSEC source: 0001127602-21-016121 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,409 F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 01:36 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 250 | $237.99 | $59,497.50 |
DisclosureSEC source: 0001127602-21-004470 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,659 F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:00 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004335 · form4.xml · derivative · entry 2 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771 Underlying: Common Stock · 986 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:00 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 986 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004335 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 18:18 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 771 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003923 · form4.xml · derivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,757 Underlying: Common Stock · 771 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 17:11 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionNon-qualified Stock Options · Derivative | 1,300 | $0.00 Strike: $98.49 | $0.00 |
DisclosureSEC source: 0001127602-21-002786 · form4.xml · derivative · entry 3 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,300 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Director stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2008 Stock Incentive Plan. F2 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column and is now fully exercisable. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 17:11 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 1,300 | $98.49 | $128,037.00 |
DisclosureSEC source: 0001127602-21-002786 · form4.xml · nonDerivative · entry 2 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 23:32 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 250 | $242.40 | $60,600.00 |
DisclosureSEC source: 0001127602-20-028671 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,909 F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. Read SEC document |
| September 21, 2020 Filed Jan 28, 2021 17:11 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GiftCommon Stock | 1,149 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002786 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,946 Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 21:42 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 250 | $242.95 | $60,737.50 |
DisclosureSEC source: 0001127602-20-023285 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,159 F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:25 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionNon-qualified Stock Options · Derivative | 1,300 | $0.00 Strike: $98.49 | $0.00 |
DisclosureSEC source: 0001127602-20-021339 · form4.xml · derivative · entry 3 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Underlying: Common Stock · 1,300 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Director stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2008 Stock Incentive Plan. F3 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column and is now fully exercisable. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:25 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 1,300 | $173.12 | $225,056.00 |
DisclosureSEC source: 0001127602-20-021339 · form4.xml · nonDerivative · entry 2 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,095 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:25 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 1,300 | $98.49 | $128,037.00 |
DisclosureSEC source: 0001127602-20-021339 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| May 06, 2020 Filed May 8, 2020 00:49 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 425 | $237.31 | $100,856.75 |
DisclosureSEC source: 0001127602-20-015857 · form4.xml · nonDerivative · entry 2 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,409 F2 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. Read SEC document |
| May 05, 2020 Filed May 8, 2020 00:49 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 846 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-015857 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,834 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 20:08 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 1,227 | $188.49 | $231,277.23 |
DisclosureSEC source: 0001127602-20-005587 · form4.xml · nonDerivative · entry 2 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,095 F2 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:08 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005587 · form4.xml · derivative · entry 3 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 986 Underlying: Common Stock · 1,227 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested fully on February 12, 2020. F3 · derivative.expiration_date: The Restricted Stock Units vested fully on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:08 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 1,227 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005587 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 06, 2020 Filed Feb 11, 2020 02:33 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 425 | $233.72 | $99,331.00 |
DisclosureSEC source: 0001127602-20-004750 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,988 F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:55 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003964 · form4.xml · derivative · entry 2 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,213 Underlying: Common Stock · 986 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| November 06, 2019 Filed Nov 7, 2019 23:22 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 425 | $215.45 | $91,566.25 |
DisclosureSEC source: 0001127602-19-032230 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,413 F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. Read SEC document |
| August 07, 2019 Filed Feb 6, 2020 19:55 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GiftCommon Stock | 1,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003964 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,095 Read SEC document |
| August 07, 2019 Filed Aug 8, 2019 23:12 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 425 | $183.04 | $77,792.00 |
DisclosureSEC source: 0001127602-19-026277 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,838 F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. Read SEC document |
| August 05, 2019 Filed Aug 7, 2019 15:40 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 500 | $162.91 | $81,455.00 |
DisclosureSEC source: 0001127602-19-026206 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,886 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| May 06, 2019 Filed May 8, 2019 12:21 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 500 | $162.20 | $81,100.00 |
DisclosureSEC source: 0001127602-19-017658 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,386 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| May 03, 2019 Filed May 7, 2019 22:33 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-017645 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,263 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. Read SEC document |
| February 13, 2019 Filed Feb 14, 2019 21:18 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 1,038 | $147.00 | $152,586.00 |
DisclosureSEC source: 0001127602-19-005996 · form4.xml · nonDerivative · entry 2 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,886 F2 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:18 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-005996 · form4.xml · derivative · entry 4 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,227 Underlying: Common Stock · 1,227 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest fully on February 12, 2020. F4 · derivative.expiration_date: The Restricted Stock Units vest fully on February 12, 2020. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:18 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 1,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-005996 · form4.xml · derivative · entry 3 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,038 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested fully on February 12, 2019. F3 · derivative.expiration_date: The Restricted Stock Units vested fully on February 12, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.